The other IDH inhibitor ivosidenib (Tibsovo®, AG-120, Agios Pharmaceuticals, Inc.)received FDA approval for the treatment of R/R AML carrying the IDH1 mutated form [200]. Here, IDH1 is linked to acute myeloid leukemia.